{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:36:00Z","timestamp":1781537760105,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371208"],"award-info":[{"award-number":["81371208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402837"],"award-info":[{"award-number":["81402837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Projects of New Drugs","award":["2014ZX09102045-005"],"award-info":[{"award-number":["2014ZX09102045-005"]}]},{"name":"National Science and Technology Major Projects of New Drugs","award":["2014ZX09102041-007"],"award-info":[{"award-number":["2014ZX09102041-007"]}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDA12040215"],"award-info":[{"award-number":["XDA12040215"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.intimp.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T05:46:16Z","timestamp":1510551976000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Intravenous immunoglobulin improves glucose control and \u03b2-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers"],"prefix":"10.1016","volume":"54","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-xiu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-qian","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2017.11.012_bb0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10053","key":"10.1016\/j.intimp.2017.11.012_bb0010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2017.11.012_bb0015","first-page":"29","article-title":"Management of blood glucose in type 2 diabetes mellitus","volume":"79","author":"Ripsin","year":"2009","journal-title":"Am. Fam. Physician"},{"issue":"11","key":"10.1016\/j.intimp.2017.11.012_bb0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.012_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.intimp.2017.11.012_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.intimp.2017.11.012_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4239\/wjd.v5.i5.697","article-title":"Targeting inflammation in diabetes: newer therapeutic options","volume":"5","author":"Agrawal","year":"2014","journal-title":"World J. Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.11.012_bb0040","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.2337\/diabetes.53.2007.S119","article-title":"Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes","volume":"53","author":"Robertson","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2017.11.012_bb0045","doi-asserted-by":"crossref","first-page":"S455","DOI":"10.2337\/diabetes.51.2007.S455","article-title":"Endoplasmic reticulum stress and the development of diabetes: a review","volume":"51","author":"Harding","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.intimp.2017.11.012_bb0050","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1210\/jc.2004-0405","article-title":"Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes","volume":"89","author":"Hull","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.012_bb0055","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1172\/JCI71981","article-title":"Autophagy defends pancreatic beta cells from human islet amyloid polypeptide-induced toxicity","volume":"124","author":"Rivera","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.012_bb0060","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI69866","article-title":"Human IAPP-induced pancreatic beta cell toxicity and its regulation by autophagy","volume":"124","author":"Shigihara","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"17","key":"10.1016\/j.intimp.2017.11.012_bb0065","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.1074\/jbc.M115.712455","article-title":"Differential activation of innate immune pathways by distinct islet amyloid polypeptide (IAPP) aggregates","volume":"291","author":"Westwell-Roper","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.012_bb0070","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.2337\/db13-0863","article-title":"Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction","volume":"63","author":"Westwell-Roper","year":"2014","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.intimp.2017.11.012_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154298","article-title":"Interleukin-1beta-targeted vaccine improves glucose control and beta-cell function in a diabetic KK-Ay mouse model","volume":"11","author":"Zha","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2017.11.012_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.11.012_bb0085","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","article-title":"IVIG treatment and prognosis in Guillain-Barre syndrome","volume":"30","author":"van Doorn","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"4 Suppl","key":"10.1016\/j.intimp.2017.11.012_bb0090","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Committee of the American Academy of allergy, immunology, use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.012_bb0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/jnnp.2006.111302","article-title":"Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy","volume":"78","author":"Kawagashira","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.intimp.2017.11.012_bb0100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archneur.1995.00540350039015","article-title":"Successful treatment of neuropathies in patients with diabetes mellitus","volume":"52","author":"Krendel","year":"1995","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.012_bb0105","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1526-4637.2009.00704.x","article-title":"Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy","volume":"10","author":"Tamburin","year":"2009","journal-title":"Pain Med."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.012_bb0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2169\/internalmedicine.40.349","article-title":"Intravenous immunoglobulin therapy for diabetic amyotrophy","volume":"40","author":"Ogawa","year":"2001","journal-title":"Intern. Med."},{"issue":"907","key":"10.1016\/j.intimp.2017.11.012_bb0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/pmj.77.907.326","article-title":"Human immunoglobulin for diabetic amyotrophy\u2014a promising prospect?","volume":"77","author":"Courtney","year":"2001","journal-title":"Postgrad. Med. J."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.012_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jdiacomp.2014.10.012","article-title":"CIDP variants in diabetes: measuring treatment response with a small nerve fiber test","volume":"29","author":"Nevoret","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.012_bb0125","first-page":"438","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus","volume":"18","author":"Fatehi","year":"2013","journal-title":"J Res Med Sci"},{"issue":"6","key":"10.1016\/j.intimp.2017.11.012_bb0130","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1210\/en.2009-1124","article-title":"XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model","volume":"151","author":"Owyang","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.intimp.2017.11.012_bb0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00125-014-3447-x","article-title":"IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice","volume":"58","author":"Westwell-Roper","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.intimp.2017.11.012_bb0140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","article-title":"Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis","volume":"29","author":"Haataja","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.intimp.2017.11.012_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-2-18","article-title":"Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers","volume":"2","author":"Kayed","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.intimp.2017.11.012_bb0150","doi-asserted-by":"crossref","first-page":"36631","DOI":"10.1038\/srep36631","article-title":"A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses","volume":"6","author":"Zha","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.012_bb0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nm.3084","article-title":"Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus","volume":"19","author":"Kiechl","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2017.11.012_bb0160","doi-asserted-by":"crossref","first-page":"832704","DOI":"10.1155\/2014\/832704","article-title":"The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy","volume":"2014","author":"Lippai","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2017.11.012_bb0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.012_bb0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/156720510790274437","article-title":"Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy","volume":"7","author":"Zerovnik","year":"2010","journal-title":"Curr. Alzheimer Res."},{"issue":"17","key":"10.1016\/j.intimp.2017.11.012_bb0175","doi-asserted-by":"crossref","first-page":"17294","DOI":"10.1074\/jbc.M500997200","article-title":"Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers","volume":"280","author":"Demuro","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.012_bb0180","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2012.02.010","article-title":"Diabetes mellitus and the beta cell: the last ten years","volume":"148","author":"Ashcroft","year":"2012","journal-title":"Cell"},{"issue":"48","key":"10.1016\/j.intimp.2017.11.012_bb0185","doi-asserted-by":"crossref","first-page":"19279","DOI":"10.1073\/pnas.1305517110","article-title":"Islet amyloid polypeptide toxicity and membrane interactions","volume":"110","author":"Cao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2017.11.012_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neuropharm.2016.02.015","article-title":"Naturally occurring autoantibodies against Abeta oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.intimp.2017.11.012_bb0195","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.012_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2017.11.012_bb0205","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","article-title":"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes","volume":"109","author":"Hundal","year":"2002","journal-title":"J. Clin. Invest."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T20:43:09Z","timestamp":1538685789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917304320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":41,"alternative-id":["S1567576917304320"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.012","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin improves glucose control and \u03b2-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}